Philips, Nuvodia pen PACS partnership

Lisa Fratt | | Health Exec | Precision Medicine
Royal Philips Electronics plans to work with Nuvodia, a wholly owned subsidiary of Inland Imaging Investments, to bring Philips PACS to rural hospitals, smaller institutions, imaging centers, orthopedic centers and oncology practices.

These facilities may lack the resources to purchase and maintain PACS, and the program will allow them to purchase Philips' IntelliSpace PACS on a fee-per-study basis, according to a release.

IntelliSpace PACS includes an application programming interface that allows application customization and interfacing with a hospital’s IT systems. Through the collaboration, Nuvodia’s eRadiology cloud will host and maintain the system database, and customers will have onsite image storage with access to its features through a web-deployable enterprise and diagnostic workstations.

Optionally, through IntelliSpace PACS, customers will be able to access Nuvodia’s eRadiology program, a service in which physicians can send images to specialists for consultations.

Lisa Fratt

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.